视网膜缺血:佩奥尼佛洛林的治疗效果和机制
Windsor Wen-Jin Chao1,2, Howard Wen-Haur Chao3, Pai-Huei Peng4
1Department of Renal Medicine, New Cross Hospital, Wolverhampton WV10 0QP, UK.
International journal of molecular sciences
|November 27, 2025
概括
佩奥尼佛洛林通过减少细胞死亡和炎症来保护视网膜缺血. 这种天然化合物表现出神经保护作用,为危及视力的眼睛疾病提供潜在的治疗益处.
科学领域:
- 眼科医生 眼科 眼科
- 神经科学是一个神经科学.
- 药理学 药理学 是一个学科.
背景情况:
- 视网膜缺血是糖尿病视网膜病变和黄斑变性等疾病中视力丧失的主要原因.
- 目前对视网膜缺血的治疗有局限性,需要探索新型治疗剂.
研究的目的:
- 在视网膜缺血模型中研究尼弗洛林的神经保护作用.
- 为了阐明涉及paeoniflorin治疗作用的分子途径.
主要方法:
- 在体外:视网膜色素上皮质 (RPE) 和神经元细胞暴露在过氧化 (H2O2) 或缺氧-葡萄糖 (OGD) 中以诱导缺血性损伤.
- 在体内:使用高眼内压力 (HIOP) 建立了视网膜缺血-再输液 (I/R) 的Wistar大鼠模型.
- 对细胞活力,视网膜功能 (ERG b波),视网膜厚度,视网膜质细胞存活率,亡以及关键分子介质 (β-catenin,HIF-1α,VEGF,Ang-2) 进行了评估.
主要成果:
- 在视网膜损伤的两种体外模型中,paeoniflorin显著增加了细胞活力.
- 在体内,佩奥尼佛洛林预治疗保留了视网膜功能,厚度和神经元存活率,同时减少了细胞亡.
- 佩奥尼佛洛林有效降低了亲血管和亲炎症因素的调节,包括β-catenin,HIF-1α,VEGF和Ang-2.
结论:
- 佩奥尼佛洛林对视网膜缺血具有显著的神经保护性.
- 它的治疗作用通过抗炎,抗血管/血管新生和抗氧化机制进行调解.
- 佩奥尼佛洛林是治疗视网膜缺血症和相关眼部疾病的有希望的治疗候选药物.
相关概念视频
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
443
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
443
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
538
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
538